Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK-626616 is a potent and orally bioavailable DYRK3 inhibitor (IC50: 0.7 nM). It inhibits other members of the DYRK family with similar potency. GSK-626616 is a potential therapy for the treatment of anemia.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 10,000 | |||
5 mg | 在庫あり | ¥ 22,500 | |||
10 mg | 在庫あり | ¥ 35,500 | |||
25 mg | 在庫あり | ¥ 68,000 | |||
50 mg | 在庫あり | ¥ 125,500 | |||
100 mg | 在庫あり | ¥ 181,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 22,500 |
説明 | GSK-626616 is a potent and orally bioavailable DYRK3 inhibitor (IC50: 0.7 nM). It inhibits other members of the DYRK family with similar potency. GSK-626616 is a potential therapy for the treatment of anemia. |
ターゲット&IC50 | β-glucuronidase:0.7 nM |
In vitro | GSK-626616 (serum-deprived HeLa cells) reduces EGF-induced phosphorylation of PRAS40 at Thr246. GSK-626616 enhances the binding of PRAS40 to mTORC1[2]. GSK-626616 abolishes the phosphorylation of S6K1 at Thr389 in nonstimulated HeLa cells. GSK-626616 reduces the phosphorylation of S6K1 at Thr389 in EGF- and insulin-stimulated HeLa cells, showing that mTORC1 activity is impaired[2]. |
分子量 | 401.27 |
分子式 | C18H10Cl2N4OS |
CAS No. | 1025821-33-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 49 mg/mL (122.11 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GSK-626616 1025821-33-3 Cell Cycle/Checkpoint Tyrosine Kinase/Adaptors DYRK GSK 626616 Inhibitor Dual specificity tyrosine regulated kinase GSK626616 inhibit Dual specificity tyrosine phosphorylation regulated kinase inhibitor